Table 1. Summary of human cancer serum samples tested in this study.
| CANCER PATIENT SERUM SAMPLES | |||||
| LOT NUMBER | GENDER | AGE | STAGE | CANCER TYPE | TREATMENT |
| BRH233781 | Female | 63 | 4 | OVARIAN CANCER | Carboplatin, Taxotere |
| BRH233782 | Female | 66 | 4 | OVARIAN CANCER | Carboplatin, Gemzar |
| BRH233787 | Female | 69 | 4 | NON-SMALL CELL LUNG | Zofr, Deca, Carb, Neul, Veps |
| BRH234151 | Female | 68 | 4 | SMALL CELL LUNG | Topotecan |
| BRH234153 | Male | 62 | 3 | SMALL CELL LUNG | Zometa |
| BRH237121 | Female | 69 | 1 | COLON CANCER | None |
| BRH237122 | Female | 67 | 2 | COLON CANCER | Ferrlecit |
| BRH237123 | Female | 85 | 2 | COLON CANCER | None |
| BRH233792 | Female | 63 | 2 | COLON CANCER | None |
| BRH237120 | Female | 87 | 3 | COLON CANCER | Zometa |
| BRH233796 | Male | 69 | 3 | COLON CANCER | 5FU |
| BRH233798 | Female | 76 | 3 | COLON CANCER | None, Pretreatment |
| BRH249639 | Male | 47 | 4 | COLON CANCER | 5FU |
| BRH234157 | Female | 80 | 4 | BREAST CANCER | Femara, Zometa |
| BRH234158 | Female | 44 | 4 | BREAST CANCER | Xeloda, Zometa |
| BRH233808 | Male | 65 | 4 | PROSTATE | Taxotere, Zometa |
| BRH233809 | Male | 62 | 4 | PROSTATE | Taxotere, Zometa |
| BRH233811 | Male | 72 | 3 | PROSTATE | Lupron, Zometa |
| BRH233812 | Male | 61 | 3 | PROSTATE | None |
| BRH233814 | Male | 59 | 3 | PROSTATE | Taxotere |
| BRH249616 | Male | 64 | 2 | PROSTATE | None |